Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Axogen, Inc. reported fourth quarter ended December 31, 2022 results: revenue $36.2 million, net income $5.4 million, EPS $0.13 per share.
- Period
- fourth quarter ended December 31, 2022
- Revenue
- $36.2 million
- Net income
- $5.4 million
- EPS
- $0.13 per share
- Result
- reported results
Exact text from the filing
Fourth Quarter 2022 Financial Results and Business Highlights • Fourth quarter revenue was $36.2 million, a 17% increase compared to fourth quarter of 2021.* • Gross margin was 83.0% for the fourth quarter compared to 82.8% in the fourth quarter of 2021.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Axogen, Inc. reported full year 2023 results: revenue $154 million to $159 million. Guidance initiated.
- Period
- full year 2023
- Revenue
- $154 million to $159 million
- Guidance
- initiated
- Result
- guidance update
Exact text from the filing
Management expects full-year 2023 revenue to be in the range of $154 million to $159 million
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Axogen, Inc. reported full year ended December 31, 2022 results: revenue $138.6 million.
- Period
- full year ended December 31, 2022
- Revenue
- $138.6 million
- Result
- reported results
Exact text from the filing
ved hospital operating environment and commercial execution, backed by our high-quality portfolio of clinical data provides a solid foundation for long term, sustainable growth.” Full-Year Financial Results and Business Highlights • Full-year 2022 revenue was $138.6 million, a 12% increase compared to 2021 revenue of $127.4 million.* • Gross margin was 82.6% for the full year, compared to 82.0% in 2021.
View on SEC.gov